To include your compound in the COVID-19 Resource Center, submit it here.

EC approves Aveo's tivozanib for RCC

The European Commission approved Fotivda tivozanib from Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) to treat advanced renal cell carcinoma. Specifically, the approval is for first-line treatment of adults with

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE